p53 peptide-pulsed dendritic cell vaccine + aromatase inhibitor

This investigational combination immunotherapy regimen, developed under the leadership of Inge Marie Svane at the Center for Cancer Immune Therapy (CCIT), is designed for the treatment of p53-positive, hormone receptor-positive (ER+/PGR+) metastatic breast cancer. The regimen integrates an autologous dendritic cell vaccine, pulsed with p53-derived peptides, with standard-of-care aromatase inhibitors (such as exemestane, letrozole, or anastrozole). The vaccine is intended to prime the patient's immune system to recognize and eliminate tumor cells overexpressing the p53 protein. The aromatase inhibitor component serves to block the synthesis of estrogen, which fuels the growth of hormone-sensitive breast cancer cells. To further enhance the vaccine-induced immune response, the protocol includes the administration of interleukin-2 (IL-2) and thymosin alpha 1 (Zadaxin) as immunomodulatory adjuvants. This multi-modal approach aims to overcome endocrine resistance and improve time to progression in patients with recurrent disease.

Brand names

ZadaxinFemaraArimidexAromasinProleukin

Other names

aromatase inhibitor-Inge Marie Svane-breast cancerp53-DC vaccine plus AIp-53-DC vaccine plus AIp 53-DC vaccine plus AIp53 peptide-pulsed autologous dendritic cellsp-53 peptide-pulsed autologous dendritic cellsp 53 peptide-pulsed autologous dendritic cellsp53-pulsed DC vaccinep-53-pulsed DC vaccinep 53-pulsed DC vaccine